Maria Kulesch, Autor bei Pava Partners Germany AG

Pava Nutraceuticals Report – First Edition

Where Growth, Complexity, and M&A Converge We are [...]

Pava Nutraceuticals Report – First EditionMaria Kulesch2026-10-19T11:29:42+02:00

Strong Fundraising Momentum, Capital Concentration and AI The [...]

Pava Health Tech Report Q1 2026Maria Kulesch2026-10-19T15:49:47+02:00

Pava Partners advised the shareholders of color parts GmbH (“color [...]

Pava Partners advises color parts on the sale of its majority stake to PREMIUM Equity PartnersMaria Kulesch2026-05-13T14:27:57+02:00

We are starting the new year with a special [...]

Pava Partners is honored as Top Company 2026Maria Kulesch2026-05-13T14:27:46+02:00

Cultural Mobility Shift: From Ownership to Usage In [...]

Pava Mobility Tech Sector Report Q3 2025Maria Kulesch2026-10-19T15:56:59+02:00

Pava Partners advised SaxonQ, the pioneer in mobile quantum [...]

Pava Partners advises SaxonQ on an investment by TGFS Technologiegründerfonds SachsenMaria Kulesch2026-03-10T13:44:53+01:00

Liebe Mandanten, liebe Partner, liebe Freunde, Wir freuen uns [...]

MedTech Expert Markus Wiegmann Joins Pava Partners as Senior AdvisorMaria Kulesch2026-02-20T08:51:13+01:00

Pava Partners advised the technology startup NorcSi, based in [...]

Pava Partners advises the technology startup NorcSi on a financing roundMaria Kulesch2026-01-29T15:27:45+01:00

Pava Partners exclusively advised Munich-based Cosinuss GmbH (“cosinuss°”) on [...]

Pava Partners exclusively advises cosinuss° on its sale to corpulsMaria Kulesch2025-11-24T16:03:12+01:00

Dear customers, dear partners, dear friends, We are delighted [...]

Semicon expert Oliver Markl strengthens partnershipMaria Kulesch2025-07-02T11:23:44+02:00

Dear clients, partners and friends, 2024 was a great [...]

2024: One of our strongest yearsMaria Kulesch2025-04-09T10:21:33+02:00

As the new year starts, we are delighted to [...]

Pava Partners is honored as Top Company 2025Maria Kulesch2025-02-17T10:38:44+01:00